Droplet-Digital PCR Provides a Rapid, Accurate and Cost-Effective Method for Identification of Biomarker FcγRIIa-F158V Genotypes

Paul Griffith¹, David Sun¹, Sarah R Tritsch¹, Caroline Jochems², James L Gulley³, Jeffrey Schlom⁴ and Xiaolin Wu⁵*
¹Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA
²Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
³Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Abstract

Development of novel monoclonal antibodies, vaccines and oncolytic virus therapies have relied on analysis of biomarkers as potential predictors of success. One well studied biomarker is the CD16/FcγRIIa receptor residue 158 F/V. Identifying variants through genotyping of the FcγRIIa locus is widely practiced and highly varied with commonly used methods including: Sanger sequencing, flow-cytometry, PCR/RFLP, Goldengate (replaced by Infinium) and TaqMAN analysis. While each of these methods have considerable backing in publications related to CD16 FcγRIIa 158 F/V, the majority present significant short comings in identifying both homozygotes (wild-type and mutant) and heterozygotes in a time and cost-efficient manner. Utilization of droplet-digital PCR with FcγRIIa-F158V specific probes results in the accurate genotyping using direct recognition of sequence in genomic samples at a lower average cost and faster turnaround. Here we demonstrate the use of ddPCR to accurately identify FcγRIIa-F158V genotypes with confirmation by Illumina sequencing in 128 patient samples.

Keywords: Biomarker; FcγRIIa; FcγRIIa-F158V; CD16; Droplet-digital PCR; ddPCR, Illumina

Introduction

Identification of novel biomarkers present an important medical progression in the cancer therapy, transplant rejection and autoimmune diseases utilizing newly developed monoclonal antibodies (mAbs) and oncolytic adenovirus treatments. Current cancer-related mAb therapies are predominated by IgG antibodies to promote identification and cytotoxic elimination of cancer cells through antibody-dependent cellular cytotoxicity (ADCC) [1,2]. One potential biomarker of significance for ADCC-based immunotherapies is CD16/FcγRIIa, a key mediator of IgG related anti-tumor activity and is associated with increased binding of mAb therapeutics to NK cells [3,4]. FcγRIIa possesses a well-studied amino acid variant in the hinge region of the protein caused by SNP 559 (T/G) resulting in the phenotype FcγRIIa- F158V (Figure 1) [5,6]. The FcγRIIa-F158V biomarker has been analyzed in studies of trastuzumab (HER2 breast cancer), rituximab (non-Hodgkin’s lymphoma, large B-cell lymphoma, Burkitt lymphoma) and cetuximab (KRAS wild-type colorectal, head and neck cancer) for correlation of either the 158F or 158V phenotype with positive outcomes [7-10]. The presence of the FcγRIIa-158V biomarker has been demonstrated to positively correlate with positive clinical outcomes in multiple mAb studies, suggesting that rapid identification of this biomarker is important support to future treatment options [8-13]. Oncolytic viruses are another novel means for treatment of cancers which have found potentially critical information relating to treatment success in FcγRIIa-F158V phenotypes [14].

Current methods for genotyping CD16-SNP559/ FcγRIIa-F158V include allele specific PCR, nested PCR/RFLP, PCR/Sanger sequencing, Goldengate genotyping, allele-specific qPCR with SYBR green, flow-cytometry and TaqMAN SNP assay, all of which are commonly utilized to this day [5,6,12,13,15-17]. The breadth of methods produces complications when comparing studies due to shortcomings and provisos associated with each method [18]. A highly homologous gene on the same chromosome (FcγRIIb) which contains a homozygous 158V phenotype can complicate the FcγRIIa-F158V genotyping result for PCR or sequencing based methods (Figure 1). Due to the FcγRIIb pseudogene, PCR analysis requires highly accurate primer design and sequencing is often a requirement for confidence in results which increases complexity, time requirements and costs [16]. Goldengate genotyping is time intensive and designed for a large number of SNPS for individuals. Due to the breadth of information garnered from Goldengate arrays, usually designed for hundreds of SNPs, resulting data beyond the CD16 SNP559 of interest and adds to the complexity and cost for analysis. Allele specific qPCR using SYBR green does not rectify concerns related to PCR analysis and requires significant optimization and does not provide sequence data. Flow-cytometry has been widely used to identify FcγRIIa-F158V via allele specific antibody interaction with FcγRIIa [19]. This method provides an accurate, but expensive means for identification of 158V/V and 158F/F phenotypes that requires a significant investment in expensive equipment or access to a flow cytometry facility. In addition to its expense, flow cytometry for FcγRIIa suffers from complications with resolving heterozygotes due to experimental shortcomings related to fluorescence and binding variations between antibodies for FcγRIIa-158F and 158V alleles [14,15], TaqMAN SNP assays are specific, highly sensitive and dependent on recognition of original (genomic) sequence for genotype calling which support their use for such analysis, however TaqMAN assays have complications related to reproducibility, statistical strength of outputs and are sensitive to PCR contaminants [15]. More importantly, the highly homologous FcγRIIb could interfere with TaqMAN assay for FcγRIIa.

Combining TaqMAN qPCR assays with ddPCR will improve the quantitative aspect of the assay significantly. The primary differentiating factor between TaqMAN and ddPCR is that the latter encapsulates PCR reactions into ~20,000 droplets prior to PCR which allows for

*Corresponding author: Xiaolin Wu, Ph.D, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA, Tel: 301-846-7877; E-mail: forestwu@mail.nih.gov

Received August 28, 2017; Accepted September 20, 2017; Published September 22, 2017


Copyright: © 2017 Griffith P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ISSN: 2329-6682 Volume 6 • Issue 2 • 1000143
Methods

**ddPCR FcyRIIIa-F158V allele-specific assay**

Droplet-digital PCR was performed using a Bio-Rad QX200 droplet generator, BioRad T-100 thermocycler for PCR and subsequent droplet analysis using a BioRad QX200 droplet reader and Quantasoft software. Primers and probes utilized were generated by ABI/Thermo-Fisher Scientific for SNP analysis (rs396991) targeting FcyRIIIa nucleotide 559 [3,21-23]. Final reaction mix consisted of: primers (900 nM each), probes (250 nM each) Bio-Rad ddPCR Supermix for Probes (no dUTP) (1X) and genomic DNA (10 to 50 ng) prior to loading into Bio-Rad QX200 droplet generator. Thermal cycling conditions utilized: 95°C for 10 minutes, (94°C for 30 seconds, 60°C for 1 minute) 40 cycles, final extension of 72°C for 10' and a 4°C indefinite hold. ddPCR FcyRIIIa-158F/V genotyping was performed by calculating the ratio of FcyRIIIa-158F/V sequences produced and were expressed as a ratio of FcyRIIIa-158F alleles and FcyRIIIa-158V allele counts per sample. Expected copy numbers of a target in a sample in a highly sensitive manner. The absolute quantification of template, providing the ability to calculate copy numbers of a target in a sample in a highly sensitive manner. The use of ddPCR over regular qPCR produces significant benefits which resolve TaqMAN related problems including significantly higher reproducibility, reduction in variability and more accurate classification of alleles [20]. In addition to the advantages over the traditional TaqMAN qPCR assays, ddPCR maintains significant accuracy, cost and time advantages over previously mentioned PCR and array-based assay types which support its use as a common and rapid means for FcyRIIIa-F158V SNP genotyping.

**Identification of FcyRIIIa-F158V genotype ratios by ddPCR**

PCR of exon 3 of CD16 was performed using Platinum® Taq DNA polymerase, 2 µL High Fidelity 10 X buffer, 0.6 µL 50 mM MgCl2, 0.4 µL 10 mM dNTP, 1 µL primers (each), 1 µL DNA (10 ng) 0.8 µL polymerase and H2O up to 20 µL. PCR reactions were performed at 95°C for 2 minutes followed by 35 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 60 or 180 seconds with a final extension of 72°C for 10 minutes and a 4°C indefinite hold. PCR products were purified using Agencourt beads and eluted with 20 µL H2O and yields confirmed using Nanodrop. Barcoding for Illumina sequencing was done with the forward primer consisting of P5,15 bar-code, PE1SP (HP10), inline barcode and M13F (5' AATGATACGGCTCACTAATATTGCAGACTACGTCAAGATGTCTCTTCCCTCTGAACTTCACAGCTCTTCAGAAGGCTAGATTGAGAGCCCTTTGTCGATACTGGTACGATGGTGAGCTCTGCCTGCATGCTTTACATATTTACAGA 3'). PCR of exon 3 of CD16 was performed using Platinum® Taq DNA polymerase, 2 µL High Fidelity 10 X buffer, 0.6 µL 50 mM MgCl2, 0.4 µL 10 mM dNTP, 1 µL primers (each), 1 µL DNA (10 ng) 0.8 µL polymerase and H2O up to 20 µL. PCR reactions were performed at 95°C for 2 minutes followed by 35 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 60 or 180 seconds with a final extension of 72°C for 10 minutes and a 4°C indefinite hold. PCR products were purified using Agencourt beads and eluted with 20 µL H2O and yields confirmed using Nanodrop. Barcoding for Illumina sequencing was done with the forward primer consisting of P5,15 bar-code, PE1SP (HP10), inline barcode and M13F (5' AATGATACGGCTCACTAATATTGCAGACTACGTCAAGATGTCTCTTCCCTCTGAACTTCACAGCTCTTCAGAAGGCTAGATTGAGAGCCCTTTGTCGATACTGGTACGATGGTGAGCTCTGCCTGCATGCTTTACATATTTACAGA 3'). Primers and probes utilized were generated by ABI/Thermo-Fisher Scientific for SNP analysis (rs396991) targeting FcyRIIIa nucleotide 559 [3,21-23]. Final reaction mix consisted of: primers (900 nM each), probes (250 nM each) Bio-Rad ddPCR Supermix for Probes (no dUTP) (1X) and genomic DNA (10 to 50 ng) prior to loading into Bio-Rad QX200 droplet generator. Thermal cycling conditions utilized: 95°C for 10 minutes, (94°C for 30 seconds, 60°C for 1 minute) 40 cycles, final extension of 72°C for 10' and a 4°C indefinite hold. ddPCR FcyRIIIa-158F/V alleles and FcyRIIIb-158V were quantified and the total fraction of FcyRIIIa-158F/V sequences produced and were expressed as a ratio with 2.0 representing expected 158 F/V wild-type, 1:1 denoting 158 F/V heterozygotes and 0:2 denoting FcyRIIIa-158 V homozygotes with all values rounded to the nearest tenth. Medians were used for analysis to decrease noise, use of averages demonstrated results consistent with presented analysis (data not shown). Peripheral blood mononuclear cells

Peripheral blood mononuclear cells (PBMCs) from healthy donors were obtained from the NIH Clinical Center Blood Bank (NCT00018846). PBMCs were also obtained from cancer patients enrolled in three phase I studies at the National Cancer Institute: Avelumab (NCT01772004), M7824 (NCT02517398), and Talactoferrin (NCT00707304).

**Results**

Identification of FcyRIIIa-F158V genotype ratios by ddPCR confidently demonstrates homozygous wild-type (2:2), heterozygotes (1:3) or homozygous mutants (0:4) at the 158 residue. FcyRIIIa-158 F/V analysis resulted in median ratios for FcyRIIIa-158 F homozygotes of 2.2 ± 0.02 (n=49), FcyRIIIa-158 F/V heterozygotes of 1.3 ± 0.01 (n=64) while FcyRIIIa-158V homozygotes resulted in median ratios of 0.4 ± 0.0 (n=17) all p<0.1 x 10^-7 (Figure 2). Subsequent Illumina sequencing
of 25 samples demonstrated median FcγRIIa-F158V ratios of 2.2 ± 0.0 (n=9) for wild-type, 1.3 ± 0.03 (n=13) for heterozygotes and 0.4 ± 0.0 (n=2) for homozygous mutants, consistent with the overall sample population (Figures 3A–3C).

Identification of FcγRIIa-F158V genotypes through sequencing analysis resulted in ratios based on a 2:0 ratio for wild-type, 1:1 ratio for heterozygotes and 0:2 ratio for homozygous mutants due to the ability to filter out results from FcγRIIib that are present in ddPCR results. Illumina MiSeq analysis for PCR products using 60 second extension times resulted median FcγRIIa-F158V ratios obtained for wild-type were 1.86±0.14 ± 0.01, heterozygotes produced a ratio of 0.94±1.06 ± 0.02 and homozygous mutant produced a ratio of 0.2 ± 0.0 all p<0.005. MiSeq analysis using PCR products with 180 second extension times resulted in median FcγRIIa-F158V ratios for wild-type of 1.88:0.12 ± 0.0 (n=2) for homozygous mutants, consistent with the overall sample population (Figures 3A–3C).

Comparison of ddPCR and Illumina MiSeq sequence data resulted in ratios based on a 2:0 ratio for wild-type, 1:1 ratio for heterozygotes and 0:2 ratio for homozygous mutants due to the ability to filter out results from FcγRIIib that are present in ddPCR results. For values which did not result in standard deviation, they were rounded normally for genotype identification.

Table 1. Comparison of ddPCR, Illumina MiSeq 60'' PCR extension and Illumina MiSeq 180'' PCR extension ratios and genotype interpretations for 25 samples. Results from ddPCR analysis of FcγRIIa-F158V genotypes agree with Illumina sequencing for all 25 samples processed indenting homozygotes and heterozygotes without bias or issue. For values which did not result in standard deviation, they were rounded normally for genotype identification.

Table 2: Comparison of estimated financial and time costs for different methods of FcγRIIa-1F58V identification based on widely-available pricing schemes. Cost do not include the associated equipment which varies between assays. Complexity is an assessment based on the number of skills, required training, and samples involved.

Figure 2: Categorization of FcγRIIa-F158V genotypes using a ddPCR assay. Droplet digital PCR is capable of consistently categorizing samples according to FcγRIIa-158V F/V genotypes (n = 128). Blue bars represent total called copies of FcγRIIa-158V while orange bars represent the total called copies of FcγRIIa-158V. A FcγRIIa-158F homozygote (left) is represented by 2 copies of FcγRIIa-158F and 2 copies of recognized FcγRIIb-158V in expected ratios while a heterozygote (middle) is represented by 1 copy of FcγRIIa-158F and 3 copies of FcγRIIa-158V while a FcγRIIa-158V homozygote is represented by four copies of FcγRIIa-158V (right). Errors bars represent standard errors and categorical identifications of F/F, V/F and V/V are statistically differentiated by the Mann-Whitney test with p < 0.1 x 10-9.

Figure 3: Comparison of ddPCR and Illumina MiSeq sequence data medians for identification of FcγRIIa-F158V genotypes. A. ddPCR results categorizing FcγRIIa-158F F/V genotypes with differentiation between F/F (left), F/V (middle) and V/V (right) genotypes in a statistically significant manner (p < 1x10-14). B. Illumina MiSeq 60'' PCR extension results illustrating differentiation between F/F (left), F/V (middle) and V/V (right) gene copy ratios at FcγRIIa-158v with categorical differences being significant (p < 0.01). C. Illumina MiSeq 180'' PCR extension results illustrating differentiation between F/F, F/V and V/V ratios at FcγRIIa-158v categorical differences being significant (p < 0.01). Errors bars represent standard error; P values were calculated using 2-tailed Student’s T-test.
the low side of a per-sample cost.
3. Cost associated with processing of samples (single reaction per sample) includes an estimate for ddPCR master mix for probes (no dUTP), TaqMAN probes/primers, gaskets/droplet cartridges and droplet oil as published by Bio-Rad (http://www.bio-rad.com/enus/category/digital-pcr) in addition to a reference set of primers/probes ($0.74/sample GAPDH) from ThermoFisher (https://www.thermofisher.com/order/catalog/product/4333764F).

ThermoFisher recommends quadruplicate processing of samples for qPCR/Taqman assays, however, triplicate is considered a standard number of replicates.

Discussion

The proliferation of mAb, vaccine and oncolytic virus therapies for wide ranging disease applications has raised the need for a rapid and accurate means to identify the clinically important FcγRIIIa-158 F/V. Droplet digital PCR readily identified FcγRIIIa-F158V genotypes of 128 samples with a subset of 25 samples being sequenced using the Illumina MiSeq platform supported all of the ddPCR results analyzed.

Results from ddPCR demonstrate minor variations in the expected ratios obtained from FcγRIIIab-158 F/V analysis. Cutoff ranges for ddPCR results were established at 1.8-2.2:1.8-2.2, 0.8-1.2:0.8-1.2 and 0.4:0.4 to categorize genotypes as FF, VF or VV respectively, with sequence data confirming that these cutoffs produced accurate genotype calls (Table 1). MiSeq results utilized cutoffs of 1.8-2.0:0.2, 0.8-1.2:0.8-1.2 and 0.0-2.1:0.1-2.0 to categorize the results as FF, VF or VV respectively (Table 1). PCR products generated using a 60 second extension time were more sensitive to these variations which, using a 1% of expected ratio cutoff, produced easily interpreted results for FcγRIIIab-158 F/V genotyping. MiSeq analysis of PCR products using a 180 second extension were more consistent with expected ratios and should be utilized in the future for any required Illumina sequencing.

Conclusion

The analysis of FcγRIIIa-F158V is increasingly vital to the field of mAb, vaccine and oncolytic virus therapies as a potential biomarker and ddPCR provides the simplest and most accurate method for a rapid determination of the genotypes of a large sample set in direct contrast to currently employed methods of analysis. Direct genotyping analysis using TaqMAN via ddPCR is provides a significant improvement over standard TaqMAN protocols, resulting in outperformance in replication and statistical power. When attributing costs of determination for FcγRIIIab-158 F/V analysis. ddPCR is further realized as a more efficient and accurate method than all current standards.

The studies reported here were performed solely for academic purposes, and the results have not been used for prognostication.

Acknowledgement

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government.

This research was supported (in part) by the National Institutes of Health.

References


